DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS DETECTION OF CANCER BIOMARKERS ON THE RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER
DEVELOPMENT OF A DUPLEX BIOCHIP ASSAY FOR THE SIMULTANEOUS DETECTION OF ANTI-THYROGLOBULIN AND ANTI-THYROID PEROXIDASE ANTIBODIES ON THE FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER
DEVELOPMENT OF NEW BIOCHIP ARRAYS FOR THE DETERMINATION OF BIOMARKERS RELATED TO ACUTE KIDNEY INJURY APPLIED TO THE EVIDENCE INVESTIGATOR ANALYSER
DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE DETECTION OF PARATHYROID HORMONE APPLIED TO THE EVIDENCE EVOLUTION ANALYSER
DEVELOPMENT OF A HIGHLY MULTIPLEXED MOLECULAR ASSAY FOR DETECTION OF INFECTION IN CF AIRWAYS
Repeatability and within-laboratory precision were assessed (n=80): Assay Repeatability Within-laboratory precision CV (%) CV (%) VCAM-1 4.5 6.8 ICAM-1 5.6 8.8 ESEL 12.8 16.6 PSEL 3.5 4.7 LSEL 5.7 8.2 17.096, 097.105RDRT DEVELOPMENT OF A BIOCHIP ARRAY FOR THE DETECTION OF ADHESION MOLECULES ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER
DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY UNAFFECTED BY DHEA-S INTERFERENCE FOR THE ACCURATE MEASUREMENT OF SERUM PROGESTERONE
DEVELOPMENT OF A BIOCHIP ARRAY FOR THE RAPID, SIMULTANEOUS DETECTION OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN 17, ON THE NEW RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER
CLINICAL EVALUATION OF A RAPID FULLY-AUTOMATED MULTIPLEX BIOCHIP ARRAY FOR STROKE DIAGNOSIS
DEVELOPMENT OF A NEW BIOCHIP ARRAY APPLIED TO THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER FOR THE SIMULTANEOUS MEASUREMENT OF TSH, FREE T4 AND FREE T3
DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE MEASUREMENT OF TOTAL 25-HYDROXYVITAMIN D IN SERUM AND THE ACCURATE CLASSIFICATION OF VITAMIN D STATUS
DEVELOPMENT OF A BIOCHIP ASSAY FOR THE DETECTION OF THYROXINE-BINDING GLOBULIN (TBG) ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER
GENETIC DIAGNOSIS OF MONOGENIC OR POLYGENIC FAMILIAL HYPERCHOLESTEROLEMIA IN NORTHERN IRELAND: EVALUATION OF THE RANDOX FH ARRAYS IN COMBINATION WITH THE RANDOX 6SNP POLYGENIC HYPERCHOLESTEROLEMIA ARRAY
DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS MEASUREMENT OF DISTINCT FATTY ACID-BINDING PROTEINS (FABPs)
DEVELOPMENT OF A NEW ENZYME-LINKED IMMUNOSORBENT ASSAY KIT TO DETECT NGAL IN HUMAN SERUM AND ITS APPLICATION TO CHRONIC KIDNEY DISEASE
SCREENING AND SELECTION OF ANTIBODIES FOR THE DETECTION OF MIP-1 ALPHA AND ITS APPLICATION TO THE STUDY OF CHRONIC KIDNEY DISEASE
DEVELOPMENT OF A 4-PLEX BIOCHIP ARRAY FOR THE EARLY DETECTION OF CHRONIC KIDNEY DISEASE
DEVELOPMENT OF A THIRD GENERATION TSH ASSAY ON THE NEW RANDOM ACCESS EVIDENCE EVOLUTION FULLY AUTOMATED BIOCHIP ANALYSER
APPLICATION OF THE NEW RANDOM ACCESS, FULLY AUTOMATED BIOCHIP ANALYSER EVIDENCE EVOLUTION TO SIMULTANEOUSLY MEASURE ANALYTES RELATED TO ENDOCRINE FUNCTION
STRATIFYING RISK OF ACUTE KIDNEY INJURY IN PRE AND POST CARDIAC SURGERY PATIENTS USING A NOVEL BIOMARKER-BASED ALGORITHM AND CLINICAL RISK SCORE
Challenge your Instrument Throughout the Reportable Range with Acusera Linearity Verifier Sets
Complimentary data reduction software is provided delivering an immediate indication of performance.
Samples are provided in a user-friendly format with both liquid and lyophilised options available.
An extended open vial stability keeps waste to a minimum and ensures availability of product for troubleshooting.
Supplied in a minimum of 5 levels to accurately challenge the AMR and remove the need for manual dilution.
Ensure specific instrument requirements are met with the availability of dedicated solution for both Roche Cobas and Beckman systems.
Multi-analyte calibration verifiers will reduce costs, storage space and the number of products required to cover your test menu.
Solutions for Roche Cobas Analysers
Solutions for Beckman Analysers
Calibration verification or linearity assessment is defined as the testing of materials of known concentration in the same manner as patient specimens to ensue the test system is accurately measuring samples throughout the reportable range.
CLIA recommend calibration verification once every six months and/or in the event of; a reagent lot change, major preventative maintenance, replacement of critical parts, when QC materials are outside acceptable limits or reflect an unusual trend and as part of new instrument validation.
Acusera Linearity Verifier Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format and in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.
Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment. Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review. To view more of our quality control products click here.
Linearity Verifier Sets | Key Features and Benefits
Click each icon for full features and benefits
Data Reduction Software
Complimentary data reduction software is provided delivering an immediate indication of performance.
Liquid Samples
All samples are provided in a user-friendly, liquid format significantly reducing preparation time and the risk of pipetting errors.
Consolidation
Reduce costs, storage space and the number of individual products required to cover your test menu with our comprehensive, multi-analyte Calibration Verifiers.
Clinically Relevant Levels
Designed to challenge the whole analytical measuring range, helping ensure accurate/reliable performance. 5 levels removes the need for manual dilution and allows for more comprehensive asses
